Guanoxabenz, an α2 adrenergic receptor agonist, exhibits properties that make it significant in biochemical research and potential therapeutic applications.

The formation of high-affinity Guanoxabenz binding is inhibited in a time- and concentration-dependent manner through preincubation with the LW03 N-hydroxyguanidine analogue of Guanoxabenz, as well as various metabolic inhibitors [allopurinol, 1-chloro-2,4-dinitrobenzene, 5,5'-dithiobis-(2-nitrobenzoic acid), cibacron blue, phenyl-p-benzoquinone, didox, and trimidox]. Additionally, the spleen cytosolic fraction reduces Guanoxabenz to guanabenz, which exhibits an almost 100-fold higher affinity for rat alpha2A-adrenoceptors than Guanoxabenz, suggesting a complex interaction between Guanoxabenz, its analogues, and metabolic inhibitors regarding their binding affinities and reduction processes.

High affinity Guanoxabenz binding is also induced in rat brain membranes after addition of NADH or NADPH cofactors. The rat cerebral cortex contains an enzymatic activity that may activate Guanoxabenz leading to formation of a metabolite showing high affinity for alpha 2-adrenoceptors.Guanoxabenz and guanabenz are both known as centrally active antihypertensive drugs.?enzymatic activity in the rat spleen can induce N-reduction of Guanoxabenz, leading to high affinity alphaα2 adrenergic receptor binding, due to the formation of theα2 adrenergic receptor active drug, guanabenz.